First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis. Issue 4 (31st October 2022)

• Record Type: Journal Article
• Authors: Liu, Tianshu; Bai, Yuxian; Lin, Xiaoyan; Li, Wei; Wang, Jufeng; Zhang, Xiaochun; Pan, Hongming; Bai, Chunmei; Bai, Li; Cheng, Ying; Zhang, Jingdong; Zhong, Haijun; Ba, Yi; Hu, Wenwei; Xu, Ruihua; Guo, Weijian; Qin, Shukui; Yang, Nong; Lu, Jianwei; Shitara, Kohei; Lei, Ming; Li, Mingshun; Bao, Nicole; Chen, Tian; Shen, Lin
• Is Part Of: International journal of cancer. Volume 152:Issue 4(2023)
• Page Start: 749
• Page End: 760
• Publication Date: 2022-10-31
• Subjects: Asian Continental Ancestry Group -- gastrointestinal neoplasms -- immunotherapy -- nivolumab -- stomach neoplasms; Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.34296
• Languages: English
• ISSNs: 0020-7136

Abstract

Abstract: First‐line chemotherapy for advanced/metastatic human epidermal growth factor receptor 2 (HER2)‐negative gastric/gastroesophageal junction cancer (GC/GEJC) has poor median overall survival (OS; <1 year). We report efficacy and safety results from Chinese patients in the phase III global CheckMate 649 study of nivolumab plus chemotherapy vs chemotherapy for the first‐line treatment of GC/GEJC/esophageal adenocarcinoma (EAC). Chinese patients with previously untreated advanced or metastatic GC/GEJC/EAC were randomized to receive nivolumab (360 mg Q3W or 240 mg Q2W) plus chemotherapy (XELOX [capecitabine and oxaliplatin] Q3W or FOLFOX [oxaliplatin, leucovorin and 5‐fluorouracil] Q2W), nivolumab plus ipilimumab (not reported) or chemotherapy alone. OS, blinded independent central review‐assessed progression‐free survival (PFS), objective response rate (ORR), duration of response (DOR) and safety are reported. Of 1581 patients enrolled and randomized, 208 were Chinese. In these patients, nivolumab plus chemotherapy resulted in clinically meaningful improvement in median OS (14.3 vs 10.2 months; HR 0.61 [95% CI: 0.44‐0.85]), median PFS (8.3 vs 5.6 months; HR 0.57 [95% CI: 0.40‐0.80]), ORR (66% vs 45%) and median DOR (12.2 vs 5.6 months) vs chemotherapy, respectively. The safety profile was acceptable, with no new safety signals observed. Consistent with results from the global primary analysis of CheckMate 649, nivolumab plus chemotherapy demonstrated a clinically meaningful improvement in OS and PFS and higher response rate vs chemotherapy and an acceptable safety profile in Chinese patients. Nivolumab plus chemotherapy represents a new standard first‐line treatment for Chinese patients with non‐HER2‐positive advanced GC/GEJC/EAC. Abstract : What's new? First‐line nivolumab plus chemotherapy demonstrated superior overall survival versus chemotherapy and an acceptable safety profile in advanced gastric/gastroesophageal junction/esophageal adenocarcinoma in the global CheckMate 649 trial. Chinese patients have high unmet need in this disease setting, and in this analysis, nivolumab plus chemotherapy demonstrated clinically meaningful improvement in efficacy versus chemotherapy with an acceptable safety profile in Chinese patients from CheckMate 649.